Capsugel Acquires Ionic Liquids Technology
Capsugel has acquired the intellectual property pertaining to proprietary ionic liquids technology developed at the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University in Australia. The technology uses lipid-like counter-ion salts to improve the solubility of drugs in lipid-based liquid, semi-solid and multiparticulate formulations. This technology adds to Capsugel Dosage Form Solutions' bioavailability enhancement technologies and capabilities.
Under the terms of the agreement, Monash University will transfer its patent application and associated results and know-how to Capsugel, effective immediately. Capsugel will also extend its existing partnership with MIPS by funding additional research positions to accelerate ongoing and future drug-delivery projects. MIPS and Capsugel have a long history of collaboration in lipid-based drug delivery science including co-founding the Lipid Formulation Classification System (LFCS) Consortium to advance and standardize evaluation protocols for lipid-based drug-delivery systems.
Source: Capsugel